Teriparatide increases bone mineral density in a man with osteoporosis pseudoglioma

Journal of Bone and Mineral Research

Volumn 26, Issue 12, 2011, Pages 2823-2826

  Arantes, Henrique Pierotti ^a   Barros, Elizabete Ribeiro ^a   Kunii, Ilda ^a   Bilezikian, John P ^b   Lazaretti Castro, Marise ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b Columbia University ^*  (United States)

Author keywords

BONE MINERAL DENSITY; BONE TURNOVER MARKERS; LRP5 MUTATION; PTH (1 34)

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; CREATININE; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; URIC ACID;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD CELL COUNT; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; CLINICAL TRIAL; CONGENITAL BLINDNESS; CREATININE URINE LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FRACTURE; GENETIC DISORDER; HIP; HORMONAL THERAPY; HUMAN; KIDNEY FUNCTION TEST; LABORATORY TEST; LIVER FUNCTION TEST; LUMBAR SPINE; MALE; MULTIPLE CYCLE TREATMENT; OSTEOPOROSIS; OSTEOPOROSIS PSEUDOGLIOMA; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TREATMENT DURATION; URIC ACID BLOOD LEVEL;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; COLLAGEN TYPE I; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOGENESIS IMPERFECTA; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TERIPARATIDE; YOUNG ADULT;

EID: 81855224871     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.530     Document Type: Article

References (25)

1. Ai M, Heeger S, Bartels CF, Schelling DK, Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis pseudoglioma syndrome. Am J Hum Genet. 2005; 77: 741-53. (Pubitemid 41513277)
2. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML, Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001; 107 (4): 513-23. (Pubitemid 33152786)
3. Lev D, Binson I, Foldes AJ, Watemberg N, Lerman-Sagie T,. Decreased bone density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma syndrome. Isr Med Assoc J. 2003; 5 (6): 419-21. (Pubitemid 37107521)
4. Streeten EA, McBride D, Puffenberger E, Hoffman ME, Pollin TI, Donnelly P, Sack P, Morton H,. Osteoporosis pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone. 2008; 43 (3): 584-90.
5. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G, Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R, Ducy P, Karsenty G,. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008; 135 (5): 825-37.
6. Barros ER, Dias da Silva MR, Kunii IS, Lazaretti-Castro M,. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J Pediatr Endocrinol Metab. 2008; 21 (8): 811-8. Erratum in: J Pediatr Endocrinol Metab. 2008 Sep; 21(9): 911.
7. Sawakami K, Robling AG, Ai M, Pitner ND, Liu D, Warden SJ, Li J, Maye P, Rowe DW, Duncan RL, Warman ML, Turner CH,. The Wnt Co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J Biol Chem. 2006; 281 (33): 23698-711. (Pubitemid 44274145)
8. Barros ER, Dias da Silva MR, Kunii IS, Hauache OM, Lazaretti-Castro M,. A novel mutation in the LRP5 gene is associated with osteoporosis-pseudoglioma syndrome. Osteoporos Int. 2007; 18 (7): 1017-8. (Pubitemid 46889561)
9. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH,. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10; 344 (19): 1434-41. (Pubitemid 32402100)
10. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M,. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004; 32 (34): 426-38. (Pubitemid 38998935)
11. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R,. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007 Nov 15; 357 (20): 2028-39. (Pubitemid 350106710)
12. Finkelstein JS, Arnold AL,. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis. J Clin Endocrinol Metab. 1999 Apr; 84 (4): 1214-9. (Pubitemid 30644378)
13. Bilezikian JP,. Clinical use of parathyroid hormone in osteoporosis. In:, Adler RA, editor. Osteoporosis-Pathophysiology and Clinical Management, 2nd edition. Clifton (NJ): Humana Press; 2010. p. 511-26.
14. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB,. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007; 22 (4): 495-502. (Pubitemid 47457425)
15. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr., Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep; 88 (9): 4214-20. (Pubitemid 37153722)
16. Rubin MR, Sliney J Jr, McMahon DJ, Silverberg SJ, Bilezikian JP,. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010 Nov; 21 (11): 1927-34.
17. Ettinger B, San Martin J, Crans G, Pavo I,. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res. 2004; 19: 745-61.
18. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP,. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008; 93: 3785-93.
19. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP,. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res. 2001 Jan; 16 (1): 104-12. (Pubitemid 32046194)
20. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS,. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001 Sep 27; 345 (13): 948-55.
21. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS,. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009; 94 (8): 2915-21.
22. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP,. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000; 85 (9): 3069-76.
23. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R,. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res. 2009; 24 (6): 1110-5.
24. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37 (2): 148-58. (Pubitemid 40962421)
25. Yadav VK, Arantes HP, Barros ER, Lazaretti-Castro M, Ducy P,. Genetic analysis of Lrp5 function in osteoblast progenitors. Calcif Tissue Int. 2010; 86 (5): 382-8.